Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | GPR183 | P32249 | 1/20 | 0.38 |
| ▸ | PDE5A | O76074 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3772605 | 1.00 | JAK2 (0.49) | JAK2POLBMAPTGPR183PDE5A | |
| SCHEMBL3769153 | 0.89 | JAK2 (0.44) | JAK2POLBMAPTPDE5ALMNA | |
| SCHEMBL3768714 | 0.89 | JAK2 (0.44) | JAK2POLBMAPTPDE5ALMNA | |
| SCHEMBL3769148 | 0.89 | JAK2 (0.44) | JAK2POLBMAPTPDE5ALMNA | |
| SCHEMBL3768711 | 0.89 | JAK2 (0.44) | JAK2POLBMAPTPDE5ALMNA | |
| SCHEMBL3773019 | 0.87 | JAK2 (0.42) | JAK2POLBMAPTPDE5A | |
| SCHEMBL3773025 | 0.87 | JAK2 (0.42) | JAK2POLBMAPTPDE5A | |
| SCHEMBL416411 | 0.86 | JAK2 (0.48) | JAK2POLBMAPTPDE5ALMNA | |
| SCHEMBL416412 | 0.86 | JAK2 (0.48) | JAK2POLBMAPTPDE5ALMNA | |
| SCHEMBL3711065 | 0.85 | JAK2 (0.51) | JAK2POLBPDE5ALMNARXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170320870-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2017-11-09 | — | — | US | disclosed |
| EP-2408772-B1 | COMPOUNDS | MEDICAL RES COUNCIL TECHNOLOGY (GB) | 2015-07-01 | — | — | EP | disclosed |
| US-8569281-B2 | Compounds and their administration for treating a neurodegenerative disease as well as a method for identifying a compound capable of inhibiting a kinase, such as LRRK | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2013-10-29 | — | — | US | disclosed |
| US-20120295883-A1 | COMPOUNDS | GENENTECH, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| US-20100317646-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295883-A1 | COMPOUNDS | ABCC5, PRNP, PC | JAK2 2080/4885POLB 3401/4885MAPT 40/4885 |
| US-20170320870-A1 | COMPOUNDS | CBR3, CNR1, HCAR3 | JAK2 1557/4885POLB 4474/4885MAPT 4568/4885 |
| US-20100317646-A1 | COMPOUNDS | CBR3, CNR1, HCAR3 | JAK2 1492/4885POLB 4468/4885MAPT 4576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.